328 results on '"Berney, S."'
Search Results
2. A New Population of Compton-Thick AGN Identified Using the Spectral Curvature Above 10 keV
- Author
-
Koss, Michael J., Assef, R., Balokovic, M., Stern, D., Gandhi, P., Lamperti, I., Alexander, D. M., Ballantyne, D. R., Bauer, F. E., Berney, S., Brandt, W. N., Comastri, A., Gehrels, N., Harrison, F. A., Lansbury, G., Markwardt, C., Ricci, C., Rivers, E., Schawinski, K., Treister, E., and Urry, C. Megan
- Subjects
Astrophysics - High Energy Astrophysical Phenomena ,Astrophysics - Astrophysics of Galaxies - Abstract
We present a new metric that uses the spectral curvature (SC) above 10 keV to identify Compton-thick AGN in low-quality Swift BAT X-ray data. Using NuSTAR, we observe nine high SC-selected AGN. We find that high-sensitivity spectra show the majority are Compton-thick (78% or 7/9) and the remaining two are nearly Compton-thick (NH~5-8x10^23 cm^-2). We find the SC_bat and SC_nustar measurements are consistent, suggesting this technique can be applied to future telescopes. We tested the SC method on well-known Compton-thick AGN and find it is much more effective than broad band ratios (e.g. 100% using SC vs. 20% using 8-24/3-8 keV). Our results suggest that using the >10 keV emission may be the only way to identify this population since only two sources show Compton-thick levels of excess in the OIII to X-ray emission ratio (F_OIII/F_2-10 keV>1) and WISE colors do not identify most of them as AGN. Based on this small sample, we find that a higher fraction of these AGN are in the final merger stage than typical BAT AGN. Additionally, these nine obscured AGN have, on average, four times higher accretion rates than other BAT-detected AGN (Edd ratio=0.068 compared to 0.016). The robustness of SC at identifying Compton-thick AGN implies a higher fraction of nearby AGN may be Compton-thick (~22%) and the sum of black hole growth in Compton-thick AGN (Eddington ratio times population percentage), is nearly as large as mildly obscured and unobscured AGN., Comment: Accepted to ApJ, 19 pages, 12 figures
- Published
- 2016
- Full Text
- View/download PDF
3. Determining the radio AGN contribution to the radio-FIR correlation using the black hole fundamental plane relation
- Author
-
Wong, O. Ivy, Koss, M. J., Schawinski, K., Kapińska, A. D., Lamperti, I., Oh, K., Ricci, C., and Berney, S.
- Subjects
Astrophysics - Astrophysics of Galaxies - Abstract
We investigate the 1.4 GHz radio properties of 92 nearby (z<0.05) ultra hard X-ray selected Active Galactic Nuclei (AGN) from the Swift Burst Alert Telescope (BAT) sample. Through the ultra hard X-ray selection we minimise the biases against obscured or Compton-thick AGN as well as confusion with emission derived from star formation that typically affect AGN samples selected from the UV, optical and infrared wavelengths. We find that all the objects in our sample of nearby, ultra-hard X-ray selected AGN are radio quiet; 83\% of the objects are classed as high-excitation galaxies (HEGs) and 17\% as low-excitation galaxies (LEGs). While these low-z BAT sources follow the radio--far-infrared correlation in a similar fashion to star forming galaxies, our analysis finds that there is still significant AGN contribution in the observed radio emission from these radio quiet AGN. In fact, the majority of our BAT sample occupy the same X-ray--radio fundamental plane as have been observed in other samples, which include radio loud AGN --- evidence that the observed radio emission (albeit weak) is connected to the AGN accretion mechanism, rather than star formation., Comment: (11 pages, 5 figures, accepted for publication in MNRAS)
- Published
- 2016
- Full Text
- View/download PDF
4. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials
- Author
-
Clowse, Megan EB, Wallace, Daniel J, Furie, Richard A, Petri, Michelle A, Pike, Marilyn C, Leszczyński, Piotr, Neuwelt, C Michael, Hobbs, Kathryn, Keiserman, Mauro, Duca, Liliana, Kalunian, Kenneth C, Galateanu, Catrinel, Bongardt, Sabine, Stach, Christian, Beaudot, Carolyn, Kilgallen, Brian, Gordon, Caroline, Batalov, A, Bojinca, M, Djerassi, R, Duca, L, Horak, P, Kolarov, Z, Milasiene, R, Monova, D, Otsa, K, Pileckyte, M, Popova, T, Radulescu, F, Rashkov, R, Rednic, S, Repin, M, Stoilov, R, Tegzova, D, Vezikova, N, Vitek, P, Zainea, C, East, Far, Baek, H, Chen, Y, Chiu, Y, Cho, C, Chou, C, Choe, J, Huang, C, Kang, Y, Kang, S, Lai, N, Lee, S, Park, W, Shim, S, Suh, C, Yoo, W, Armengol, H Avila, Zapata, F Avila, Santiago, M Barreto, Cavalcanti, F, Chahade, W, Costallat, L, Keiserman, M, Alcala, J Orozco, Remus, C Ramos, Roimicher, L, Abu‐Shakra, M, Agarwal, V, Agmon‐Levin, N, Kadel, J, Levy, Y, Mevorach, D, Paran, D, Reitblat, T, Rosner, I, Shobha, V, Sthoeger, Z, Zisman, D, Ayesu, K, Berney, S, Box, J, Busch, H, Buyon, J, Carter, J, Chi, J, Clowse, M, Collins, R, Dao, K, Diab, I, Dikranian, A, El‐Shahawy, M, Gaylis, N, Grossman, J, Halpert, E, Huff, J, Jarjour, W, Kao, A, Katz, R, Kennedy, A, Khan, M, Kivitz, A, Kohen, M, and Lawrence‐Ford, T
- Subjects
Autoimmune Disease ,Clinical Trials and Supportive Activities ,Clinical Research ,Lupus ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Inflammatory and immune system ,Adult ,Antibodies ,Monoclonal ,Humanized ,Double-Blind Method ,Female ,Humans ,Lupus Erythematosus ,Systemic ,Male ,Severity of Illness Index ,Treatment Outcome ,EMBODY Investigator Group ,Clinical Sciences ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology - Abstract
ObjectiveEpratuzumab, a monoclonal antibody that targets CD22, modulates B cell signaling without substantial reductions in the number of B cells. The aim of this study was to report the results of 2 phase III multicenter randomized, double-blind, placebo-controlled trials, the EMBODY 1 and EMBODY 2 trials, assessing the efficacy and safety of epratuzumab in patients with moderately to severely active systemic lupus erythematosus (SLE).MethodsPatients met ≥4 of the American College of Rheumatology revised classification criteria for SLE, were positive for antinuclear antibodies and/or anti-double-stranded DNA antibodies, had an SLE Disease Activity Index 2000 (SLEDAI-2K) score of ≥6 (increased disease activity), had British Isles Lupus Assessment Group 2004 index (BILAG-2004) scores of grade A (severe disease activity) in ≥1 body system or grade B (moderate disease activity) in ≥2 body systems (in the mucocutaneous, musculoskeletal, or cardiorespiratory domains), and were receiving standard therapy, including mandatory treatment with corticosteroids (5-60 mg/day). BILAG-2004 grade A scores in the renal and central nervous system domains were excluded. Patients were randomized 1:1:1 to receive either placebo, epratuzumab 600 mg every week, or epratuzumab 1,200 mg every other week, with infusions delivered for the first 4 weeks of each 12-week dosing cycle, for 4 cycles. Patients across all 3 treatment groups also continued with their standard therapy. The primary end point was the response rate at week 48 according to the BILAG-based Combined Lupus Assessment (BICLA) definition, requiring improvement in the BILAG-2004 score, no worsening in the BILAG-2004 score, SLEDAI-2K score, or physician's global assessment of disease activity, and no disallowed changes in concomitant medications. Patients who discontinued the study medication were classified as nonresponders.ResultsIn the EMBODY 1 and EMBODY 2 trials of epratuzumab, 793 patients and 791 patients, respectively, were randomized, 786 (99.1%) and 788 (99.6%), respectively, received study medication, and 528 (66.6%) and 533 (67.4%), respectively, completed the study. There was no statistically significant difference in the primary end point between the groups, with the week 48 BICLA response rates being similar between the epratuzumab groups and the placebo group (response rates ranging from 33.5% to 39.8%). No new safety signals were identified.ConclusionIn patients with moderate or severely active SLE, treatment with epratuzumab + standard therapy did not result in improvements in response rates over that observed in the placebo + standard therapy group.
- Published
- 2017
5. [O III]$\lambda 5007$ and X-ray Properties of a Complete Sample of Hard X-ray Selected AGNs in the Local Universe
- Author
-
Ueda, Y., Hashimoto, Y., Ichikawa, K., Ishino, Y., Kniazev, A. Y., Vaisanen, P., Ricci, C., Berney, S., Gandhi, P., Koss, M., Mushotzky, R., Terashima, Y., Trakhtenbrot, B., and Crenshaw, M.
- Subjects
Astrophysics - High Energy Astrophysical Phenomena - Abstract
We study the correlation between the [O III]$\lambda 5007$ and X-ray luminosities of local Active Galactic Nuclei (AGNs), using a complete, hard X-ray ($>10$ keV) selected sample in the Swift/BAT 9-month catalog. From our optical spectroscopic observations at the South African Astronomical Observatory and the literature, a catalog of [O III]$\lambda 5007$ line flux for all 103 AGNs at Galactic latitudes of $|b|>15^\circ$ is complied. Significant correlations with intrinsic X-ray luminosity ($L_{\rm X}$) are found both for observed ($L_{\rm [O~III]}$) and extinction-corrected ($L_{\rm [O~III]}^{\rm cor}$) luminosities, separately for X-ray unabsorbed and absorbed AGNs. We obtain the regression form of $L_{\rm [O~III]}$ $\propto L_{\rm 2-10\; keV}^{1.18\pm0.07}$ and $L_{\rm [O~III]}^{\rm cor}$ $\propto L_{\rm 2-10\; keV}^{1.16\pm0.09}$ from the whole sample. The absorbed AGNs with low ($<$0.5\%) scattering fractions in soft X-rays show on average smaller $L_{\rm [O~III]}/L_{\rm X}$ and $L_{\rm [O~III]}^{\rm cor}/L_{\rm X}$ ratios than the other absorbed AGNs, while those in edge-on host galaxies do not. These results suggest that a significant fraction of this population are buried in tori with small opening angles. By using these $L_{\rm [O~III]}$ vs. $L_{\rm X}$ correlations, the X-ray luminosity function of local AGNs (including Compton thick AGNs) in a standard population synthesis model gives much better agreement with the [O III]$\lambda 5007$ luminosity function derived from the Sloan Digital Sky Survey than previously reported. This confirms that hard X-ray observations are a very powerful tool to find AGNs with high completeness., Comment: 14 pages including 11 figures and 3 tables, accepted for publication in ApJ. In this manuscript, the observed 14-195 keV luminosities in Table 1 have been corrected to be exactly the same as in the original Swift/BAT 9-month catalog. Accordingly, Figures 2(a) and 3(a) and a part of Tables 2 and 3 have been updated. The changes from the previous version are small and do not affect the text
- Published
- 2015
- Full Text
- View/download PDF
6. Responsiveness of Critically Ill Adults With Multimorbidity to Rehabilitation Interventions: A Patient-Level Meta-Analysis Using Individual Pooled Data From Four Randomized Trials
- Author
-
Jones, JRA, Karahalios, A, Puthucheary, ZA, Berry, MJ, Files, DC, Griffith, DM, McDonald, LA, Morris, PE, Moss, M, Nordon-Craft, A, Walsh, T, Berney, S, Denehy, L, Jones, JRA, Karahalios, A, Puthucheary, ZA, Berry, MJ, Files, DC, Griffith, DM, McDonald, LA, Morris, PE, Moss, M, Nordon-Craft, A, Walsh, T, Berney, S, and Denehy, L
- Abstract
OBJECTIVE: To explore if patient characteristics (pre-existing comorbidity, age, sex, and illness severity) modify the effect of physical rehabilitation (intervention vs control) for the coprimary outcomes health-related quality of life (HRQoL) and objective physical performance using pooled individual patient data from randomized controlled trials (RCTs). DATA SOURCES: Data of individual patients from four critical care physical rehabilitation RCTs. STUDY SELECTION: Eligible trials were identified from a published systematic review. DATA EXTRACTION: Data sharing agreements were executed permitting transfer of anonymized data of individual patients from four trials to form one large, combined dataset. The pooled trial data were analyzed with linear mixed models fitted with fixed effects for treatment group, time, and trial. DATA SYNTHESIS: Four trials contributed data resulting in a combined total of 810 patients (intervention n = 403, control n = 407). After receiving trial rehabilitation interventions, patients with two or more comorbidities had HRQoL scores that were significantly higher and exceeded the minimal important difference at 3 and 6 months compared with the similarly comorbid control group (based on the Physical Component Summary score (Wald test p = 0.041). Patients with one or no comorbidities who received intervention had no HRQoL outcome differences at 3 and 6 months when compared with similarly comorbid control patients. No patient characteristic modified the physical performance outcome in patients who received physical rehabilitation. CONCLUSIONS: The identification of a target group with two or more comorbidities who derived benefits from the trial interventions is an important finding and provides direction for future investigations into the effect of rehabilitation. The multimorbid post-ICU population may be a select population for future prospective investigations into the effect of physical rehabilitation.
- Published
- 2023
7. Barriers and enablers to telehealth use by physiotherapists during the COVID-19 pandemic
- Author
-
Haines, KJ, Sawyer, A, McKinnon, C, Donovan, A, Michael, C, Cimoli, C, Gregory, M, Berney, S, Berlowitz, DJ, Haines, KJ, Sawyer, A, McKinnon, C, Donovan, A, Michael, C, Cimoli, C, Gregory, M, Berney, S, and Berlowitz, DJ
- Abstract
OBJECTIVES: To investigate the perceived barriers and enablers experienced by physiotherapists whilst delivering community and outpatient services during the COVID-19 pandemic. METHODS: Qualitative study undertaken at a University-affiliated hospital in Melbourne, Australia. Physiotherapists working in the outpatient setting participated in a semi-structured interview. Interviews were analysed using Framework Analysis, with themes mapped to the Theoretical Domains Framework (TDF). RESULTS: From 19 interviews, we identified major themes and mapped these to the TDF domains: 1. The pandemic rapidly closed the knowledge-practice gap; 2. Adaptation of existing skills and integration of new skills were required; 3. Supportive senior leadership helped the transition; 4. Capabilities and confidence improved with time; 5. Environmental factors were crucial to success or failure of telehealth; 6. Access to and delivery of care improved for some; 7. Identification of appropriate patients and future hybrid models of care; 8. Changes in work practices, role certainty and identity; 9. Development of educational resources consolidated knowledge; 10. Socialisation of telehealth and optimism for the future. Within each domain, key barriers and enablers were also identified. CONCLUSIONS: The findings of this study suggest that the delivery of community and outpatient physiotherapy via telehealth during the COVID-19 pandemic was an initial challenge. Growing knowledge, confidence and ability to problem solve barriers enabled physiotherapists to move along the continuum of 'fear' to 'triumph' as the pandemic progressed. These results can be used by clinicians, managers, and academics to guide future workforce planning, hospital environmental design, and service delivery. CLINICAL MESSAGE.
- Published
- 2023
8. Development, feasibility testing, and preliminary evaluation of the Communication with an Artificial airway Tool (CAT): Results of the Crit-CAT pilot study.
- Author
-
Zaga, CJ, Papasavva, CS, Hepworth, G, Freeman-Sanderson, A, Happ, MB, Hoit, JD, McGrath, BA, Pandian, V, Rose, L, Sutt, A-L, Tuinman, PR, Wallace, S, Bellomo, R, Vogel, AP, Berney, S, Zaga, CJ, Papasavva, CS, Hepworth, G, Freeman-Sanderson, A, Happ, MB, Hoit, JD, McGrath, BA, Pandian, V, Rose, L, Sutt, A-L, Tuinman, PR, Wallace, S, Bellomo, R, Vogel, AP, and Berney, S
- Abstract
BACKGROUND: A purpose-built outcome measure for assessing communication effectiveness in patients with an artificial airway is needed. OBJECTIVES: The objective of this study was to develop the Communication with an Artificial airway Tool (CAT) and to test the feasibility and to preliminary evaluate the clinical metrics of the tool. METHODS: Eligible patients with an artificial airway in the Intensive Care Unit were enrolled in the pilot study (Crit-CAT). The CAT was administered at least twice before and after the communication intervention. Item correlation analysis was performed. Participant and family member acceptability ratings and feedback were solicited. A qualitative thematic analysis was undertaken. RESULTS: Fifteen patients with a mean age of 53 years (standard deviation [SD]: 19.26) were included. The clinician-reported scale was administered on 50 attempts (100%) with a mean completion time of 4.5 (SD: 0.77) minutes. The patient-reported scale was administered on 46 out of 49 attempts (94%) and took a mean of 1.5 (SD: 0.39) minutes to complete. The CAT was feasible for use in the Intensive Care Unit, with patients with either an endotracheal or tracheostomy tube, whilst receiving invasive mechanical ventilation or not, and while using either verbal or nonverbal modes of communication. Preliminary establishment of responsiveness, validity, and reliability was made. The tool was acceptable to participants and their family members. CONCLUSION: The clinician-reported and patient-reported components of the study were feasible for use. The CAT has the potential to enable quantifiable comparison of communication interventions for patients with an artificial airway. Future research is required to determine external validity and reliability.
- Published
- 2023
9. Defining effective communication for critically ill patients with an artificial airway: An international multi-professional consensus.
- Author
-
Zaga, CJ, Freeman-Sanderson, A, Happ, MB, Hoit, JD, McGrath, BA, Pandian, V, Quraishi-Akhtar, T, Rose, L, Sutt, A-L, Tuinman, PR, Wallace, S, Bellomo, R, Berney, S, Vogel, AP, Zaga, CJ, Freeman-Sanderson, A, Happ, MB, Hoit, JD, McGrath, BA, Pandian, V, Quraishi-Akhtar, T, Rose, L, Sutt, A-L, Tuinman, PR, Wallace, S, Bellomo, R, Berney, S, and Vogel, AP
- Abstract
OBJECTIVES: To define effective communication and identify its key elements specific to critically ill patients with an artificial airway. DESIGN: A modified Consensus Development Panel methodology. SETTING: International video-conferences. MAIN OUTCOME MEASURES: Definition of effective communication and it's key elements. RESULTS: Eight experts across four international regions and three professions agreed to form the Consensus Development Panel together with a Chair and one person with lived experience who reviewed the outputs prior to finalisation. "Communication for critically ill adult patients with an artificial airway (endotracheal or tracheostomy tube) is defined as the degree in which a patient can initiate, impart, receive, and understand information, and can range from an ineffective to effective exchange of basic to complex information between the patient and the communication partner(s). Effective communication encompasses seven key elements including: comprehension, quantity, rate, effort, duration, independence, and satisfaction. In critically ill adults, communication is impacted by factors including medical, physical and cognitive status, delirium, fatigue, emotional status, the communication partner and the nature of the ICU environment (e.g., staff wearing personal protective equipment, noisy equipment, bright lights)." The panel agreed that communication occurs on a continuum from ineffective to effective for basic and complex communication. CONCLUSION: We developed a definition and list of key elements which constitute effective communication for critically ill patients with an artificial airway. These can be used as the basis of standard terminology to support future research on the development of communication-related outcome measurement tools in this population. IMPLICATIONS FOR CLINICAL PRACTICE: This study provides international multi-professional consensus terminology and a definition of effective communication which can be used in clinica
- Published
- 2023
10. Multimorbidity drives responsiveness to rehabilitation in critical illness: A patient level meta-analysis of four randomized trials
- Author
-
Jones, J, primary, Puthucheary, Z, additional, Karahalios, A, additional, Berry, M, additional, Files, D C, additional, Griffith, D, additional, Mcdonald, L, additional, Morris, P, additional, Moss, M, additional, Nordon-Craft, A, additional, Walsh, T, additional, Berney, S, additional, and Denehy, L, additional
- Published
- 2022
- Full Text
- View/download PDF
11. The sit-to-stand test as a patient-centered functional outcome for critical care research: a pooled analysis of five international rehabilitation studies
- Author
-
O'Grady, HK, Edbrooke, L, Farley, C, Berney, S, Denehy, L, Puthucheary, Z, Kho, ME, O'Grady, HK, Edbrooke, L, Farley, C, Berney, S, Denehy, L, Puthucheary, Z, and Kho, ME
- Abstract
BACKGROUND: With ICU mortality rates decreasing, it is increasingly important to identify interventions to minimize functional impairments and improve outcomes for survivors. Simultaneously, we must identify robust patient-centered functional outcomes for our trials. Our objective was to investigate the clinimetric properties of a progression of three outcome measures, from strength to function. METHODS: Adults (≥ 18 years) enrolled in five international ICU rehabilitation studies. Participants required ICU admission were mechanically ventilated and previously independent. Outcomes included two components of the Physical Function in ICU Test-scored (PFIT-s): knee extensor strength and assistance required to move from sit to stand (STS); the 30-s STS (30 s STS) test was the third outcome. We analyzed survivors at ICU and hospital discharge. We report participant demographics, baseline characteristics, and outcome data using descriptive statistics. Floor effects represented ≥ 15% of participants with minimum score and ceiling effects ≥ 15% with maximum score. We calculated the overall group difference score (hospital discharge score minus ICU discharge) for participants with paired assessments. RESULTS: Of 451 participants, most were male (n = 278, 61.6%) with a median age between 60 and 66 years, a mean APACHE II score between 19 and 24, a median duration of mechanical ventilation between 4 and 8 days, ICU length of stay (LOS) between 7 and 11 days, and hospital LOS between 22 and 31 days. For knee extension, we observed a ceiling effect in 48.5% (160/330) of participants at ICU discharge and in 74.7% (115/154) at hospital discharge; the median [1st, 3rd quartile] PFIT-s difference score (n = 139) was 0 [0,1] (p < 0.05). For STS assistance, we observed a ceiling effect in 45.9% (150/327) at ICU discharge and in 77.5% (79/102) at hospital discharge; the median PFIT-s difference score (n = 87) was 1 [0, 2] (p < 0.05). For 30 s STS, we observed a floor effect in 15.0% (
- Published
- 2022
12. Development of a physical function outcome measure (PFIT) and a pilot exercise training protocol for use in intensive care
- Author
-
Berney, S, Skinner, EH, Denehy, L, and Warrillow, S
- Published
- 2009
13. Outcomes analysis of Internet-based CME initiatives for diagnosis and treatment of fibromyalgia patients: transition from education to physician behavior to patient health
- Author
-
Somasekhar MM, Berney S, Rausch C, and Degnan J
- Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Melinda M Somasekhar,1 Steven Berney,2 Chris Rausch,1 James Degnan31The Albert J Finestone Office for Continuing Medical Education, 2Section of Rheumatology, Temple University School of Medicine, 3Measurement and Research Center, Temple University, Philadelphia, PA, USAAbstract: A well designed outcomes research study was performed in which 20 primary care physicians were selected to participate. Each physician had more than 30 fibromyalgia patients in their practice. The study design consisted of four phases. In phase one, physicians undertook a self-assessment of their practice. Phase two of the study involved diagnosis and treatment of a virtual case vignette. The third phase consisted of analysis of the data from phase two and providing feedback from an expert rheumatologist, and the fourth phase was to complete patient report forms for five patients in their practice. The year-long study was completed by 12 physicians and resulted in data on 60 patients. The results of this study provide an insight into how physicians are diagnosing and treating patients with fibromyalgia. In this study, we transition from continuing medical education to physician behavior to patient outcomes.Keywords: outcomes analysis, Internet, continuing medical education, diagnosis, treatment, fibromyalgia
- Published
- 2012
14. Direct Intervention Is Needed
- Author
-
Spivack, Berney S.
- Published
- 2008
15. Antibody against Viruses in Maternal and Cord Sera: Specific Antibody Is Concentrated on the Fetal Side of the Circulation
- Author
-
Griffiths, P. D., Berney, S. I., Argent, S., and Heath, R. B.
- Published
- 1982
16. Factors Impacting Early Mobilization Following Hip Fracture: An Observational Study
- Author
-
Said, CM, Delahunt, M, Ciavarella, V, Al Maliki, D, Boys, A-M, Vogrin, S, Berney, S, Said, CM, Delahunt, M, Ciavarella, V, Al Maliki, D, Boys, A-M, Vogrin, S, and Berney, S
- Abstract
BACKGROUND AND PURPOSE: Hip fracture guidelines emphasize mobilization within 48 hours of surgery. The aims of this audit were to determine the proportion of patients with hip fracture who mobilize within 48 hours, identify factors associated with delayed mobilization, and identify barriers to mobilization. METHODS: Single-site prospective audit of 100 consecutive patients (age 82 ± 9 years) admitted for surgical management of hip fracture. Data collected included time to mobilization, factors that may impact mobilization (age, weight-bearing status, additional injuries, premorbid mobility status, time to surgery, dementia, delirium, and postoperative complications), and barriers to mobilization as identified by the physical therapist. RESULTS AND DISCUSSION: Mobilization within 48 hours of surgery was achieved by 43% of patients. Multivariate logistic regression demonstrated odds of mobilizing early increased with higher New Mobility Scores, representing better premorbid mobility (odds ratio [OR] = 1.30; 95% confidence interval [CI], 1.06-1.60); odds reduced if delirium was present on day 1 or 2 (OR = 0.25; 95% CI, 0.08-0.79). New Mobility Scores 5 or more, which indicate independent premorbid mobility inside and outside the house, best predicted early mobilization in patients who did not develop delirium. No cutoff score was identified for those with delirium. Identified barriers to mobilization included patient confusion, manual handling risk, patient declined, and hypotension. CONCLUSIONS: Less than half of this cohort achieved the guideline of mobilization within 48 hours of surgery. Patients who develop delirium within the first 2 days of surgery or who had premorbid mobility limitation were less likely to mobilize. Identification of patients likely to have delayed mobilization will assist physical therapists with delivering appropriate management to patients with hip fracture during their acute hospital stay.
- Published
- 2021
17. Recumbent cycling to improve outcomes in people with hip fracture: a feasibility randomized trial
- Author
-
Said, CM, Delahunt, M, Hardidge, A, Smith, P, Tran, P, McDonald, L, Kefalianos, E, Daniel, C, Berney, S, Said, CM, Delahunt, M, Hardidge, A, Smith, P, Tran, P, McDonald, L, Kefalianos, E, Daniel, C, and Berney, S
- Abstract
BACKGROUND: Early mobilization after surgery is a key recommendation for people with hip fracture, however this is achieved by only 50% of people. Recumbent bike riding has been used in other populations with limited mobility and has potential to allow early exercise in people post hip fracture. The primary aim of this pilot trial was to demonstrate the feasibility of a trial protocol designed to determine the effect of early post-operative cycling in bed on outcomes in people with hip fracture. METHODS: Single-blinded, multi-site randomized controlled pilot trial. Fifty-one people with hip fracture were recruited within 4 days of surgery from two sites in Victoria. Participants were randomly allocated to receive either usual care (n = 25) or usual care plus active cycling in bed (n = 26). The cycling intervention was delivered on weekdays until the participant could walk 15 m with assistance of one person. The primary outcomes were trial feasibility and safety. Clinical outcomes, including mobility (Modified Iowa Level of Assistance Scale) and delirium were measured at day seven post-operatively and at hospital discharge by an assessor blinded to group. Additional outcomes at discharge included gait speed, cognition and quality of life. RESULTS: The intervention was safe, feasible and acceptable to patients and staff. Delivery of the intervention was ceased on (median) day 9.5 (IQR 7, 12); 73% of scheduled sessions were delivered; (median) 4 sessions (IQR 2.0, 5.5) were delivered per participant with (median) 9 min 34 s (IQR 04:39, 17:34) of active cycling per session. The trial protocol was feasible, however at day seven 75% of participants had not met the criterion (able to walk 15 m with assistance of one person) to cease the cycling intervention.. CONCLUSION: In bed cycling is feasible post-operatively following hip fracture, however seven days post-operatively is too early to evaluate the impact of the cycling intervention as many participants were still recei
- Published
- 2021
18. Immunosuppressive therapy after solid-organ transplantation: does the INTERMED identify patients at risk of poor adherence?
- Author
-
Michaud L, Ludwig G, Berney S, Rodrigues S, Niquille A, Santschi V, Favre AS, Lange AC, Michels AA, Vrijens B, Bugnon O, Pilon N, Pascual M, Venetz JP, Stiefel F, and Schneider MP.
- Subjects
Organ Transplantation ,Medication Adherence ,Personality Assessment ,Adaptation ,Psychological ,Patient Care Team ,Switzerland ,Therapeutics. Pharmacology ,RM1-950 ,Pharmacy and materia medica ,RS1-441 - Abstract
Background: Lack of adherence to medication is a trigger of graft rejection in solid-organ transplant (SOT) recipients. Objective: This exploratory study aimed to assess whether a biopsychosocial evaluation using the INTERMED instrument before transplantation could identify SOT recipients at risk of suboptimal post-transplantation adherence to immunosuppressant drugs. We hypothesized that complex patients (INTERMED>20) might have lower medication adherence than noncomplex patients (INTERMED≤20). Methods: Each patient eligible for transplantation at the University Hospital of Lausanne, Switzerland, has to undergo a pre-transplantation psychiatric evaluation. In this context the patient was asked to participate in our study. The INTERMED was completed pre-transplantation, and adherence to immunosuppressive medication was monitored post-transplantation by electronic monitors for 12 months. The main outcome measure was the implementation and persistence to two calcineurin inhibitors, cyclosporine and tacrolimus, according to the dichotomized INTERMED score (>20 or ≤20). Results: Among the 50 SOT recipients who completed the INTERMED, 32 entered the study. The complex (N=11) and noncomplex patients (N=21) were similar in terms of age, sex and transplanted organ. Implementation was 94.2% in noncomplex patients versus 87.8% in complex patients (non-significant p-value). Five patients were lost to follow-up: one was non-persistent, and four refused electronic monitoring. Of the four patients who refused monitoring, two were complex and withdrew early, and two were noncomplex and withdrew later in the study. Conclusion: Patients identified as complex pre-transplant by the INTERMED tended to deviate from their immunosuppressant regimen, but the findings were not statistically significant. Larger studies are needed to evaluate this association further, as well as the appropriateness of using a nonspecific biopsychosocial instrument such as INTERMED in highly morbid patients who have complex social and psychological characteristics.
- Published
- 2016
- Full Text
- View/download PDF
19. Response to physical rehabilitation and recovery trajectories following critical illness: individual participant data meta-analysis protocol
- Author
-
Jones, JRA, Berney, S, Berry, MJ, Files, DC, Griffith, DM, McDonald, LA, Morris, PE, Moss, M, Nordon-Craft, A, Walsh, T, Gordon, I, Karahalios, A, Puthucheary, Z, Denehy, L, Jones, JRA, Berney, S, Berry, MJ, Files, DC, Griffith, DM, McDonald, LA, Morris, PE, Moss, M, Nordon-Craft, A, Walsh, T, Gordon, I, Karahalios, A, Puthucheary, Z, and Denehy, L
- Abstract
INTRODUCTION: The number of inconclusive physical rehabilitation randomised controlled trials for patients with critical illness is increasing. Evidence suggests critical illness patient subgroups may exist that benefit from targeted physical rehabilitation interventions that could improve their recovery trajectory. We aim to identify critical illness patient subgroups that respond to physical rehabilitation and map recovery trajectories according to physical function and quality of life outcomes. Additionally, the utilisation of healthcare resources will be examined for subgroups identified. METHODS AND ANALYSIS: This is an individual participant data meta-analysis protocol. A systematic literature review was conducted for randomised controlled trials that delivered additional physical rehabilitation for patients with critical illness during their acute hospital stay, assessed chronic disease burden, with a minimum follow-up period of 3 months measuring performance-based physical function and health-related quality of life outcomes. From 2178 records retrieved in the systematic literature review, four eligible trials were identified by two independent reviewers. Principal investigators of eligible trials were invited to contribute their data to this individual participant data meta-analysis. Risk of bias will be assessed (Cochrane risk of bias tool for randomised trials). Participant and trial characteristics, interventions and outcomes data of included studies will be summarised. Meta-analyses will entail a one-stage model, which will account for the heterogeneity across and the clustering between studies. Multiple imputation using chained equations will be used to account for the missing data. ETHICS AND DISSEMINATION: This individual participant data meta-analysis does not require ethical review as anonymised participant data will be used and no new data collected. Additionally, eligible trials were granted approval by institutional review boards or research eth
- Published
- 2020
20. Genetic Relationships between Desmothoracid Heliozoa and Gymnophryid Amoebas as Evidenced by Comparison of the Nucleotide Sequences of 18S rRNA Genes
- Author
-
Nikolaev, S. I., Berney, S., Fahrni, J., Mylnikov, A. P., Petrov, N. B., and Pawlowski, J.
- Published
- 2003
- Full Text
- View/download PDF
21. Formulation de cas de Monsieur H
- Author
-
Ambresin, G., primary, Beretta, V., additional, and Berney, S., additional
- Published
- 2010
- Full Text
- View/download PDF
22. Présentation clinique
- Author
-
Berney, S., primary and Despland, J.-N., additional
- Published
- 2010
- Full Text
- View/download PDF
23. L’organisation de personnalité
- Author
-
Berney, S., primary and Despland, J.-N., additional
- Published
- 2010
- Full Text
- View/download PDF
24. Activated T-Lymphocytes Express Occludin, a Component of Tight Junctions
- Author
-
Alexander, J. S., Dayton, T., Davis, C., Hill, Stephen, Jackson, T. Haller, Blaschuk, Orest, Symonds, Matthew, Okayama, Naotsuka, Kevil, Chris G., Laroux, F. Stephen, Berney, S. M., and Kimpel, D.
- Published
- 1998
- Full Text
- View/download PDF
25. Associations between nutritional energy delivery, bioimpedance spectroscopy and functional outcomes in survivors of critical illness
- Author
-
Fetterplace, K, Beach, LJ, MacIsaac, C, Presneill, J, Edbrooke, L, Parry, SM, Rechnitzer, T, Curtis, R, Berney, S, Deane, AM, Denehy, L, Fetterplace, K, Beach, LJ, MacIsaac, C, Presneill, J, Edbrooke, L, Parry, SM, Rechnitzer, T, Curtis, R, Berney, S, Deane, AM, and Denehy, L
- Abstract
BACKGROUND: Patients who survive critical illness frequently develop muscle weakness that can impact on quality of life; nutrition is potentially a modifiable risk factor. The present study aimed to explore the associations between cumulative energy deficits (using indirect calorimetry and estimated requirements), nutritional and functional outcomes. METHODS: A prospective single-centre observational study of 60 intensive care unit (ICU) patients, who were mechanically ventilated for at least 48 h, was conducted. Cumulative energy deficit was determined from artificial nutrition delivery compared to targets. Measurements included: (i) at recruitment and ICU discharge, weight, fat-free mass (bioimpedance spectroscopy) and malnutrition (Subjective Global Assessment score B/C); (ii) at awakening and ICU discharge, physical function (Physical Function in Intensive Care Test-scored) and muscle strength (Medical Research Council sum-score (MRC-SS). ICU-acquired weakness was defined as a MRC-SS score of less than 48/60. RESULTS: The median (interquartile range) cumulative energy deficit compared to the estimated targets up to ICU day 12 was 3648 (2514-5650) kcal. Adjusting for body mass index, age and severity of illness, cumulative energy deficit (per 1000 kcal) was independently associated with greater odds of ICU-acquired weakness [odds ratio (OR) = 2.1, 95% confidence interval (CI) = 1.4-3.3, P = 0.001] and malnutrition (OR = 1.9, 95% CI = 1.1-3.2, P = 0.02). In similar multivariable linear models, cumulative energy deficit was associated with reductions in fat-free mass (-1.3 kg; 95% CI = -2.4 to -0.2, P = 0.02) and physical function scores (-0.6 points; 95% CI = -0.9 to -0.3, P = 0.001). CONCLUSIONS: Cumulative energy deficit from artificial nutrition support was associated with reduced functional outcomes and greater loss of fat-free mass in ventilated ICU patients.
- Published
- 2019
26. CAN EARLY EXTUBATION AND INTENSIVE PHYSIOTHERAPY DECREASE LENGTH OF STAY OF ACUTE QUADRIPLEGIC PATIENTS IN INTENSIVE CARE? A RETROSPECTIVE CASE CONTROL STUDY
- Author
-
Berney, S, Stockton, K, Denehy, L, and Berlowitz, D
- Published
- 2001
27. A COMPARISON OF THE EFFECTS OF MANUAL AND VENTILATOR HYPERINFLATION ON STATIC LUNG COMPLIANCE AND SPUTUM PRODUCTION IN INTUBATED AND VENTILATED INTENSIVE CARE PATIENTS
- Author
-
Berney, S, Denehy, L, and Silvester, W
- Published
- 2001
28. Associations between nutritional energy delivery, bioimpedance spectroscopy and functional outcomes in survivors of critical illness
- Author
-
Fetterplace, K., primary, Beach, L. J., additional, MacIsaac, C., additional, Presneill, J., additional, Edbrooke, L., additional, Parry, S. M., additional, Rechnitzer, T., additional, Curtis, R., additional, Berney, S., additional, Deane, A. M., additional, and Denehy, L., additional
- Published
- 2019
- Full Text
- View/download PDF
29. Spontaneous ulcerations of the breast
- Author
-
Matlock, S. M., primary, Rush, J. L., additional, Afzal, W., additional, Fulton, E. H., additional, Berney, S. M., additional, and Wong, H. K., additional
- Published
- 2019
- Full Text
- View/download PDF
30. Long-term recovery following critical illness in an Australian cohort
- Author
-
Haines, KJ, Berney, S, Warrillow, S, Denehy, L, Haines, KJ, Berney, S, Warrillow, S, and Denehy, L
- Abstract
BACKGROUND: Almost all data on 5-year outcomes for critical care survivors come from North America and Europe. The aim of this study was to investigate long-term mortality, physical function, psychological outcomes and health-related quality of life in a mixed intensive care unit cohort in Australia. METHODS: This longitudinal study evaluated 4- to 5-year outcomes. Physical function (six-minute walk test) and health-related quality of life (Short Form 36 Version 2) were compared to 1-year outcomes and population norms. New psychological data (Center for Epidemiological Studies-Depression, Impact of Events Scale) was collected at follow-up. RESULTS: Of the 150 participants, 66 (44%) patients were deceased by follow-up. Fifty-six survivors were included with a mean (SD) age of 64 (14.2). Survivors' mean (SD) six-minute walk distance increased between 1 and 4 to 5 years (465.8 m (148.9) vs. 507.5 m (118.2)) (mean difference = - 24.5 m, CI - 58.3, 9.2, p = 0.15). Depressive symptoms were low: median (IQR) score of 7.0 (1.0-15.0). The mean level of post-traumatic stress symptoms was low-median (IQR) score of 1.0 (0-11.0)-with only 9 (16%) above the threshold for potentially disordered symptoms. Short-Form 36 Physical and Mental Component Scores did not change between 1 and 4 to 5 years (46.4 (7.9) vs. 46.7 (8.1) and 48.8 (13) vs. 48.8 (11.1)) and were within a standard deviation of normal. CONCLUSIONS: Outcomes of critical illness are not uniform across nations. Mortality was increased in this cohort; however, survivors achieved a high level of recovery for physical function and health-related quality of life with low psychological morbidity at follow-up. TRIAL REGISTRATION: The trial was registered with the Australian New Zealand Clinical Trials Registry ACTRN12605000776606.
- Published
- 2018
31. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials
- Author
-
Clowse, Megan E. B, Wallace, Daniel J., Furie, Richard A., Petri, Michelle A., Pike, Marilyn C., Leszczyński, Piotr, Neuwelt, C. Michael, Hobbs, Kathryn, Keiserman, Mauro, Duca, Liliana, Kalunian, Kenneth C., Galateanu, Catrinel, Bongardt, Sabine, Stach, Christian, Beaudot, Carolyn, Kilgallen, Brian, Gordon, Caroline, Batalov, A., Bojinca, M., Djerassi, R., Duca, L., Horak, P., Kolarov, Z., Milasiene, R., Monova, D., Otsa, K., Pileckyte, M., Popova, T., Radulescu, F., Rashkov, R., Rednic, S., Repin, M., Stoilov, R., Tegzova, D., Vezikova, N., Vitek, P., Zainea, C., East, Far, Baek, H., Chen, Y., Chiu, Y., Cho, C., Chou, C., Choe, J., Huang, C., Kang, Y., Kang, S., Lai, N., Lee, S., Park, W., Shim, S., Suh, C., Yoo, W., Armengol, H. Avila, Zapata, F. Avila, Santiago, M. Barreto, Cavalcanti, F., Chahade, W., Costallat, L., Keiserman, M., Alcala, J. Orozco, Remus, C. Ramos, Roimicher, L., Abu Shakra, M., Agarwal, V., Agmon Levin, N., Kadel, J., Levy, Y., Mevorach, D., Paran, D., Reitblat, T., Rosner, I., Shobha, V., Sthoeger, Z., Zisman, D., Ayesu, K., Berney, S., Box, J., Busch, H., Buyon, J., Carter, J., Chi, J., Clowse, M., Collins, R., Dao, K., Diab, I., Dikranian, A., El Shahawy, M., Gaylis, N., Grossman, J., Halpert, E., Huff, J., Jarjour, W., Kao, A., Katz, R., Kennedy, A., Khan, M., Kivitz, A., Kohen, M., Lawrence Ford, T., Lawson, J., Levesque, M., Lowenstein, M., Majjhoo, A., Mcarthur, R., Mclain, D., Merrill, J., Murillo, A., Neucks, S., Niemer, G., Noaiseh, G., Parker, C., Pantojas, C., Pattanaik, D., Petri, M., Pickrell, P., Reveille, J., Roman Miranda, A., Rothfield, N., Sankoorikal, A., Sayers, M., Singhal, A., Snyder, A., Striebich, C., Vo, Q., von Feldt, J., Wallace, D., Wasko, M., Young, C., Adelstein, S., Hall, S., Littlejohn, G., Nicholls, D., Suranyi, M., Amoura, Z., Bannert, B., Behrens, F., Perez, L. Carreno, Chakravarty, K., Gonzales, F. Diaz, Davies, K., Doria, Andrea, Emery, P., Fernández Nebro, A., Govoni, M., Hachulla, E., Hellmich, B., Houssiau, F., Malaise, M., Margaux, J., Maugars, Y., Muñoz Fernández, S., Navarro, F., Ordi Ros, J., Pellerito, R., Pena Sagredo, J., Roussou, E., Schmidt, R. E., Ucar Angulo, E., Viallard, J. F., Westhovens, R., Worm, M., Yee, C. S., Nayiager, S., Reuter, H., Spargo, C., Bazela, B., Brzosko, M., Chudzik, D., Gasztonyi, B., Geher, P., Ionescu, R., Jeka, S., Kemeny, L., Kiss, E., Kotyla, P., Kovacs, L., Kovalenko, V., Kucharz, E., Kwiatkowska, B., Leszczynski, P., Levchenko, E., Lysenko, G., Majdan, M., Mihailov, C., Nalotov, S., Nedelciu, M., Pavel, M., Raskina, T., Rebrov, B., Rezus, E., Semen, T., Smakotina, S., Stanislavchuk, M., Stanislav, M., Szombati, I., Szucs, G., Udrea, G., Zajdel, J., Zon Giebel, A., Bonfiglioli, R., Bustamante, R., Klumb, E., Ramirez, G. Medrano, Neiva, C., Olguin, M., Gonzaga, J. Reyes, Scotton, A., Ayala, S. Sicsik, Ximenes, A., Sharma, R., Srikantiah, C., Aelion, J., Aranow, C., Baker, M., Chadha, A., Chao, J., Chatham, W., Chow, A., Clay, C., Cohen Gadol, S., Conaway, D., Denburg, J., Escalante, A., Espinoza, L., Fiechtner, J., Fortin, I., Fraser, A., Furie, R., Gladman, D., Goddard, D., Goldberg, M., Gonzalez Rivera, R., Gorman, J., Griffin, R., Haaland, D., Halter, D., Hemaiden, A., Hobbs, K., Joshi, V., Lim, S., Kalunian, K., Karpouzas, G., Khraishi, M., Lafyatis, R., Lidman, R., Lue, C., Mohan, M., Mease, P., Mehta, C., Mizutani, W., Nami, A., Nascimento, J., Neuwelt, C., Pappas, J., Pope, J., Porges, A., Roane, G., Rosenberg, D., Ross, S., Saadeh, C., Scoville, C., Sherrer, Y., Solomon, M., Surbeck, W., Valenzuela, G., Waller, P., Alten, R., Baerwald, C., Bienvenu, B., Bombardieri, S., Braun, J., Dival, L., Espinosa, G., Fernandez, I. Figueroa, Gomez Reino, J., Gordon, C., Hiepe, F., Hopkinson, N., Isenberg, D., Jacobi, A., Jorgensen, C., Guern, V. Le, Paul, C., Pego Reigosa, J. M., Heredia, J. Rodriguez, Rubbert Roth, A., Sabbadini, M., Schroeder, J., Schwarting, A., Spieler, W., Valesini, G., Wollenhaupt, J., Mendoza, A. Zea, and Zouboulis, C.
- Subjects
humanized ,adult ,rheumatology ,monoclonal ,antibodies, monoclonal, humanized ,double-blind method ,female ,humans ,lupus erythematosus, systemic ,male ,severity of illness index ,treatment outcome ,immunology and allergy ,immunology ,systemic ,Antibodies, Monoclonal, Humanized ,Systemic Lupus Erythematosus ,NO ,Immunology and Allergy ,Rheumatology ,Immunology ,Lupus Erythematosus, Systemic ,antibodies ,lupus erythematosus - Abstract
Objective Epratuzumab, a monoclonal antibody that targets CD22, modulates B cell signaling without substantial reductions in the number of B cells. The aim of this study was to report the results of 2 phase III multicenter randomized, double‐blind, placebo‐controlled trials, the EMBODY 1 and EMBODY 2 trials, assessing the efficacy and safety of epratuzumab in patients with moderately to severely active systemic lupus erythematosus (SLE). Methods Patients met ≥4 of the American College of Rheumatology revised classification criteria for SLE, were positive for antinuclear antibodies and/or anti–double‐stranded DNA antibodies, had an SLE Disease Activity Index 2000 (SLEDAI‐2K) score of ≥6 (increased disease activity), had British Isles Lupus Assessment Group 2004 index (BILAG‐2004) scores of grade A (severe disease activity) in ≥1 body system or grade B (moderate disease activity) in ≥2 body systems (in the mucocutaneous, musculoskeletal, or cardiorespiratory domains), and were receiving standard therapy, including mandatory treatment with corticosteroids (5–60 mg/day). BILAG‐2004 grade A scores in the renal and central nervous system domains were excluded. Patients were randomized 1:1:1 to receive either placebo, epratuzumab 600 mg every week, or epratuzumab 1,200 mg every other week, with infusions delivered for the first 4 weeks of each 12‐week dosing cycle, for 4 cycles. Patients across all 3 treatment groups also continued with their standard therapy. The primary end point was the response rate at week 48 according to the BILAG‐based Combined Lupus Assessment (BICLA) definition, requiring improvement in the BILAG‐2004 score, no worsening in the BILAG‐2004 score, SLEDAI‐2K score, or physician's global assessment of disease activity, and no disallowed changes in concomitant medications. Patients who discontinued the study medication were classified as nonresponders. Results In the EMBODY 1 and EMBODY 2 trials of epratuzumab, 793 patients and 791 patients, respectively, were randomized, 786 (99.1%) and 788 (99.6%), respectively, received study medication, and 528 (66.6%) and 533 (67.4%), respectively, completed the study. There was no statistically significant difference in the primary end point between the groups, with the week 48 BICLA response rates being similar between the epratuzumab groups and the placebo group (response rates ranging from 33.5% to 39.8%). No new safety signals were identified. Conclusion In patients with moderate or severely active SLE, treatment with epratuzumab + standard therapy did not result in improvements in response rates over that observed in the placebo + standard therapy group.
- Published
- 2017
32. Spontaneous ulcerations of the breast.
- Author
-
Matlock, S. M., Rush, J. L., Afzal, W., Fulton, E. H., Berney, S. M., and Wong, H. K.
- Subjects
CONTINUING medical education ,BREAST ,QUESTIONING - Abstract
Click here for the corresponding questions to this CME article. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
33. A new population of Compton-thick AGN identified using the spectral curvature above 10 keV
- Author
-
Koss, M.J., Assef, R., Balokovic, M., Stern, D., Gandhi, P., Lamperti, I., Alexander, D.M., Ballantyne, D.R., Bauer, F.E., Berney, S., Brandt, W.N., Comastri, A., Gehrels, N., Harrison, F.A., Lansbury, G., Markwardt, C., Ricci, C., Rivers, E., Treister, E., and Megan Urry, C.
- Published
- 2016
34. A012 – CURRENT UTILIZATION OF AEROBIC EXERCISE IN ADULT NEUROLOGICAL REHABILITATION BY CANADIAN PHYSIOTHERAPISTS
- Author
-
Mehta, SP, MacDermid, JC, Butcher, SJ, Pikaluk, BJ, Heynen, NM, Chura, RL, Farthing, JP, Marciniuk, DD, MacKay-Lyons, M, Doyle, L, MacDonald, T, Law, M, Burgos-Martinez, G, Fleet, A, Che, M, MacKenzie, D, Page, S, Boe, S, Woznowski-Vu, A, Preuss, R, Shaw, JA, Connelly, DM, McWilliam, CL, Shaw, J, Sidhu, K, Kearney, C, Keeber, M, McKay, S, Hopkins-Rosseel, D, Bergsma, K, Van Bavel, C, Fricke, M, Swinamer, J, Winn, CS, Tryssenaar, J, Chisholm, BA, Hummelbrunner, JA, Kandler, LS, Jasper, L, Daniels, J, Haennel, RG, Johnson, R, Martin, B, Norman, KE, Booth, R, Chisholm, B, Ellerton, C, Jelley, W, MacPhail, A, Mooney, P, Mori, B, Taipalus, L, Thomas, B, Duval, G, Ghali, S, Nasirian, A, Santillo, G, Yang, XL, Thomas, A, McKinley, P, Kaizer, F, Desveaux, L, Nanavaty, G, Howell, P, Sundar, R, Ryan, J, Verrier, M, Dutton, TL, Langendoen, T, Marshall, J, Coghill, C, Pederson, C, Blechinger, C, Marshall, M, Hamilton, CB, Chesworth, BM, Styles-Tripp, F, Sheps, D, Bury, J, Bouliane, M, Glasgow, R, Otto, D, Luciak-Corea, C, Beaupre, L, Balyk, R, Carson, S, Graham, J, Hopman, W, Parsons, T, Sawant, A, Overend, T, Prasanna, SS, Korner-Bitensky, N, Ahmed, S, O’Donovan, MJ, Driver, H, Randhawa, BK, Farley, BG, Boyd, LA, Henderson, R, Najafi, B, Bansberg, J, Druja, G, Hinch, S, Sikkema, A, Subramanian, SK, LourenÇo, CB, Chilingaryan, G, Sveistrup, H, Levin, MF, King, J, Chamberland, P, Agar, A, Leger, R, Michaels, R, Poitras, R, Rawji, A, Skelton, D, Warren, M, Lavallée, L, LeBlanc, C, McKim, D, Woolnough, A, Cockburn, L, Wango, J, Benuh, E, Cleaver, S, Madill, SJ, Pontbriand-Drolet, S, Prud’homme-Delage, A, Tang, A, Dumoulin, C, Hiemstra, LA, Lafave, M, Kerslake, S, Heard, M, Buchko, G, Mohtadi, N, Auais, M, Eilayyan, O, Mayo, N, Otfinowski, C, Fung, J, Smallhorn, P, Diez, d’Aux N, Shan, He F, Li, L, Ren, Y, Perez, C, Spahija, J, Sadeghi, M, Ebrahimi, S, Maroufi, N, Jamshidi, AA, Chepeha, JC, Magee, DJ, Warren, S, Storey, AST, Brinkman, DM, Bauck, RA, Myrah, AM, Friess, SN, Webber, SC, Taphorn, A, Magnus, CRA, Arnold, CM, Johnston, G, Dal-Bello, Haas V, Basran, J, Krentz, JR, Berardi, D, Brizard, M, Brière, H, Charron, M, Gagnon, I, Tran, T, Kasymjanova, G, Grossman, M, Xenopoulos, T, Jagoe, T, Agulnik, J, Small, D, Kinlin, C, Marlow, T, Donald, LA, Tiessen, S, Cooper, N, Pryse-Phillips, S, Yoshida, K, Teachman, G, Wright, V, Fehlings, D, Young, N, McKeever, P, Parent, EC, Breitkreitz, R, Ladd, J, McIntosh, K, Pauls, D, Urhbach, S, Koppenhaver, S, Alderdice, C, Evans, J, Feldman, S, Robinson, S, White, L, Long, A, McDougall, M, Bonnet, F, Brososky, C, Hopcroft, L, Bester, L, Clement, D, Quigley, A, Sachdeva, M, Rourke, S, Nixon, S, Mendes, P, Robles, P, Mathur, S, Warmington, K, Kennedy, C, Lundon, K, Rozmovits, L, Lineker, S, Shupak, R, Schneider, R, Kennedy, CA, Soever, L, Passalent, L, Katie, Lundon K, Roots, RK, Bainbridge, L, Brown, H, Li, LC, Gillis, K, Augruso, A, Coe, T, O’Neill, A, Radford, L, Gibson, BE, O’Callaghan, L, Bath, B, Janzen, B, Lovo, Grona S, Bourassa, R, Reilly, J, Prendergast, M, Derbyshire, M, Anderson, CM, Friedman, D, Gilbert, G, Lazowski, D, Hurtubise, K, Cote, N, McGlasson, Emery, C, Woodhouse, L, Jones, A, Dickinson, D, Torrance, G, Landry, MD, Murphy, SM, Rivard, LM, Levac, D, Aisen, M, French, EH, Barclay-Goddard, R, Dubouloz, CJ, Schwartz, CE, Jam, B, Manns, PJ, McDonald, A, Ploughman, M, Evans, C, Zhan, J, Stevens, M, Asmundson, Gordon, Yardley, D, Funk, S, Yeung, E, Sinclair, L, Damp, Lowery C, Denehy, L, Ziegler, T, LaRocque, D, Clarke, L, Edge-Hughes, LM, Budiselic, S, Berney, S, Rankin, A, Juricic, M, Peddie, E, Johnson, A, and Seminowicz, DA
- Subjects
Innovation in Education ,Practice Models and Policy ,Divisions ,Abstracts, CPA Congress 2012 ,Proposals ,Guest Editorial ,Physiotherapy Research: Basic Science through Population Health ,Best Practice - Published
- 2012
35. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
- Author
-
Tak, Pp, Rigby, Wf, Rubbert Roth, A, Peterfy, Cg, van Vollenhoven RF, Stohl, W, Hessey, E, Chen, A, Tyrrell, H, Shaw, Tm, Aelion J, IMAGE I. n. v. e. s. t. i. g. a. t. o. r. s., Afif, N, Ahmadi, F, Aires, F, Alanis, E, Alonso, Cs, Alten, Rh, Alvaro Gracia JM, Ashrafzadeh, A, Ballina, J, Bambara, Lm, Bao, C, Bell, M, Berney, S, Bessette, L, Birbara, C, Boling, E, Bourgeois, P, Braun, J, Briones, H, Brzezicki, J, Burgos Vargos, R, Burmester, G, Burnett, M, Busch, H, Cabello, E, Calvo, A, Cantagrel, A, Cantini, F, Zea, Ac, Carreño Perez, L, Chavez, J, Shim, Sc, Chindalore, V, Chiriac, R, Codding, C, Danda, D, Del Guidice, J, De Vita, S, Digiovanni, R, Dikranian, A, Eider, W, Fantini, F, Ferraccioli, G, Fietchner, J, Filipowicz Sosnowska, A, Finnanger, B, Fiocco, G, Fleck, M, Fleischmann, R, Fraser, A, Gaudin, P, Gauler, G, Gaylis, N, Gerlag, Dm, Godde, J, Gomez Reino JJ, Gornisiewicz, M, Gough, W, Greenwald, M, Guerra, G, Hackshaw, K, Haentzschel, Hm, Hammond, T, Hazleman, Bl, Heilig, B, Herenius, Mm, Hilliquin, P, Holt, D, Huang, F, Huff, J, Huizinga, T, Isaacs, J, Jaffer, A, Amante, Ej, Jeka, S, Jimenez, R, Jones, G, Jones, R, Kaine, J, Kashif, A, Kaufmann, C, Kay, J, Khraishi, M, Kivitz, A, Klinkhoff, A, Kraag, G, Krystufkova, O, Kucharz, E, Lawson, J, Leirisalo Repo, M, Levin, R, Liang, G, Liang, P, Limonta, M, Lowenstein, M, Rodriguez Lozano, C, Lue, C, Mahowald, M, Maradiaga, M, Maricic, M, Mariette, X, Martin, L, Massarotti, E, Matucci Cerinic, M, Montecucco, Cm, Mazurov, V, Mcnally, J, Mehta, D, Meyer, O, Misra, R, Moreland, Lw, Mueller Ladner, U, Myerson, G, Nasonov, E, Navarra, S, Navarro, F, Neal, N, Olech, E, Olsen, N, Pablos, Jl, Pacheco, C, Pal, S, Palomo, Er, Pandith, V, Penserga, Eg, Prupas, H, Radominski, S, Ramos Remus, C, Reid, D, Riordan, K, Rosenberg, D, Ruiz, A, Saadeh, C, Salvarani, Carlo, Samuels, A, Sanmarti, R, Sarzi Puttini, P, Saxe, P, Schechtman, J, Scoville, C, Sedlackova, M, Sedrish, M, Sejer Hansen, M, Sibilia, J, Siebert, S, Specker, C, Stern, S, Szechinski, J, Tahir, H, Taylor, A, Thompson, Pw, Tony, Hp, Tornero, J, Trapp, R, Tremblay, Jl, Valesini, G, Van Den Bosch, F, Wanchu, A, Wassenberg, S, Ximenes, Ac, Kim, Hy, Zanetakis, E, Zazueta, B, Zerbini, C., Faculteit der Geneeskunde, AII - Amsterdam institute for Infection and Immunity, Clinical Immunology and Rheumatology, and Other departments
- Subjects
Adult ,musculoskeletal diseases ,medicine.medical_specialty ,Adolescent ,Immunology ,610 Medizin ,Arthritis ,Severity of Illness Index ,Gastroenterology ,Drug Administration Schedule ,General Biochemistry, Genetics and Molecular Biology ,law.invention ,Arthritis, Rheumatoid ,Antibodies, Monoclonal, Murine-Derived ,Young Adult ,Double-Blind Method ,Rheumatology ,Randomized controlled trial ,law ,immune system diseases ,Internal medicine ,medicine ,Clinical endpoint ,Humans ,Immunology and Allergy ,heterocyclic compounds ,skin and connective tissue diseases ,Aged ,Aged, 80 and over ,ddc:610 ,business.industry ,Middle Aged ,medicine.disease ,Surgery ,Clinical trial ,Methotrexate ,Treatment Outcome ,Antirheumatic Agents ,Rheumatoid arthritis ,Disease Progression ,Drug Therapy, Combination ,Rituximab ,business ,medicine.drug - Abstract
Objectives: Rituximab is an effective treatment in patients with established rheumatoid arthritis (RA). The objective of the IMAGE study was to determine the efficacy of rituximab in the prevention of joint damage and its safety in combination with methotrexate (MTX) in patients initiating treatment with MTX. Methods: In this double-blind randomised controlled phase III study, 755 MTX-naïve patients with active RA were randomly assigned to MTX alone, rituximab 2×500 mg + MTX or rituximab 2×1000 mg + MTX. The primary end point at week 52 was the change in joint damage measured using a Genant-modified Sharp score. Results: 249, 249 and 250 patients were randomly assigned to MTX alone, rituximab 2×500 mg + MTX or rituximab 2×1000 mg + MTX, respectively. At week 52, treatment with rituximab 2×1000 mg + MTX compared with MTX alone was associated with a reduction in progression of joint damage (mean change in total modified Sharp score 0.359 vs 1.079; p=0.0004) and an improvement in clinical outcomes (ACR50 65% vs 42%; p
- Published
- 2011
- Full Text
- View/download PDF
36. BAT AGN Spectroscopic Survey. V. X-Ray Properties of the Swift /BAT 70-month AGN Catalog
- Author
-
Ricci, C., primary, Trakhtenbrot, B., additional, Koss, M. J., additional, Ueda, Y., additional, Del Vecchio, I., additional, Treister, E., additional, Schawinski, K., additional, Paltani, S., additional, Oh, K., additional, Lamperti, I., additional, Berney, S., additional, Gandhi, P., additional, Ichikawa, K., additional, Bauer, F. E., additional, Ho, L. C., additional, Asmus, D., additional, Beckmann, V., additional, Soldi, S., additional, Baloković, M., additional, Gehrels, N., additional, and Markwardt, C. B., additional
- Published
- 2017
- Full Text
- View/download PDF
37. A binational multicenter pilot feasibility randomized controlled trial of early goal-directed mobilization in the ICU.
- Author
-
Hodgson, C., Bailey, M., Bellomo, R., Berney, S., Buhr, H., Denehy, L., Gabbe, B., Harrold, Megan, Higgins, A., Iwashyna, T., Papworth, R., Parke, R., Patman, S., Presneill, J., Saxena, M., Skinner, E., Tipping, C., Young, P., Webb, S., Hodgson, C., Bailey, M., Bellomo, R., Berney, S., Buhr, H., Denehy, L., Gabbe, B., Harrold, Megan, Higgins, A., Iwashyna, T., Papworth, R., Parke, R., Patman, S., Presneill, J., Saxena, M., Skinner, E., Tipping, C., Young, P., and Webb, S.
- Abstract
Objectives: To determine if the early goal-directed mobilization intervention could be delivered to patients receiving mechanical ventilation with increased maximal levels of activity compared with standard care.Design: A pilot randomized controlled trial.Setting: Five ICUs in Australia and New Zealand.Participants: Fifty critically ill adults mechanically ventilated for greater than 24 hours.Intervention: Patients were randomly assigned to either early goal-directed mobilization (intervention) or to standard care (control). Early goal-directed mobilization comprised functional rehabilitation treatment conducted at the highest level of activity possible for that patient assessed by the ICU mobility scale while receiving mechanical ventilation.Measurements and Main Results: The ICU mobility scale, strength, ventilation duration, ICU and hospital length of stay, and total inpatient (acute and rehabilitation) stay as well as 6-month post-ICU discharge health-related quality of life, activities of daily living, and anxiety and depression were recorded. The mean age was 61 years and 60% were men. The highest level of activity (ICU mobility scale) recorded during the ICU stay between the intervention and control groups was mean (95% CI) 7.3 (6.3–8.3) versus 5.9 (4.9–6.9), p = 0.05. The proportion of patients who walked in ICU was almost doubled with early goal-directed mobilization (intervention n = 19 [66%] vs control n = 8 [38%]; p = 0.05). There was no difference in total inpatient stay (d) between the intervention versus control groups (20 [15–35] vs 34 [18–43]; p = 0.37). There were no adverse events.Conclusions: Key Practice Points: Delivery of early goal-directed mobilization within a randomized controlled trial was feasible, safe and resulted in increased duration and level of active exercises.
- Published
- 2016
38. The ICU Mobility Scale Has Construct and Predictive Validity and Is Responsive A Multicenter Observational Study
- Author
-
Tipping, C., Bailey, M., Bellomo, R., Berney, S., Buhr, H., Denehy, L., Harrold, Megan, Holland, A., Higgins, A., Iwashyna, T., Needham, D., Presneill, J., Saxena, M., Skinner, E., Webb, S., Young, P., Zanni, J., Hodgson, C., Tipping, C., Bailey, M., Bellomo, R., Berney, S., Buhr, H., Denehy, L., Harrold, Megan, Holland, A., Higgins, A., Iwashyna, T., Needham, D., Presneill, J., Saxena, M., Skinner, E., Webb, S., Young, P., Zanni, J., and Hodgson, C.
- Abstract
Rationale: The ICU Mobility Scale (IMS) is a measure of mobility milestones in critically ill patients. Objectives: This study aimed to determine the validity and responsiveness of the IMS from a prospective cohort study of adults admitted to the intensive care unit (ICU). Methods: Construct and predictive validity were assessed by comparing IMS values at ICU discharge in 192 patients to other variables using Spearman rank correlation coefficient, Mann-Whitney U tests, and logistic regression. Responsiveness was assessed using change over time, effect size, floor and ceiling effects, and percentage of patients showing change. Measurements and Main Results: The IMS at ICU discharge demonstrated a moderate correlation with muscle strength (r = 0.64, P < 0.001). There was a significant difference between the IMS at ICU discharge in patients with ICU-acquired weakness (median, 4.0; interquartile range, 3.0–5.0) compared with patients without (median, 8.0; interquartile range, 5.0–8.0; P < 0.001). Increasing IMS values at ICU discharge were associated with survival to 90 days (odds ratio [OR], 1.38; 95% confidence interval [CI], 1.14–1.66) and discharge home (OR, 1.16; 95% CI, 1.02–1.32) but not with return to work at 6 months (OR, 1.09; 95% CI, 0.92–1.28). The IMS was responsive with a significant change from study enrolment to ICU discharge (d = 0.8, P < 0.001), with IMS values increasing in 86% of survivors during ICU admission. No substantial floor (14% scored 0) or ceiling (4% scored 10) effects were present at ICU discharge. Conclusions: Our findings support the validity and responsiveness of the IMS as a measure of mobility in the ICU.
- Published
- 2016
39. A NEW POPULATION OF COMPTON-THICK AGNs IDENTIFIED USING THE SPECTRAL CURVATURE ABOVE 10 keV
- Author
-
Koss, Michael J., primary, Assef, R., additional, Baloković, M., additional, Stern, D., additional, Gandhi, P., additional, Lamperti, I., additional, Alexander, D. M., additional, Ballantyne, D. R., additional, Bauer, F. E., additional, Berney, S., additional, Brandt, W. N., additional, Comastri, A., additional, Gehrels, N., additional, Harrison, F. A., additional, Lansbury, G., additional, Markwardt, C., additional, Ricci, C., additional, Rivers, E., additional, Schawinski, K., additional, Trakhtenbrot, B., additional, Treister, E., additional, and Urry, C. Megan, additional
- Published
- 2016
- Full Text
- View/download PDF
40. Determining the radio active galactic nuclei contribution to the radio–far-infrared correlation using the black hole Fundamental Plane relation
- Author
-
Wong, O. Ivy, primary, Koss, M. J., additional, Schawinski, K., additional, Kapińska, A. D., additional, Lamperti, I., additional, Oh, K., additional, Ricci, C., additional, Berney, S., additional, and Trakhtenbrot, B., additional
- Published
- 2016
- Full Text
- View/download PDF
41. Health-related quality of life in australasian survivors of H1N1 influenza undergoing mechanical ventilation a multicenter cohort study.
- Author
-
Skinner E.H., Mulvany K., Di Marco E., Seller D., McArthur C.J., Denehy L., Hodgson C.L., Howe B., Haines K.J., Berney S., Ryan D.T., Skinner E.H., Mulvany K., Di Marco E., Seller D., McArthur C.J., Denehy L., Hodgson C.L., Howe B., Haines K.J., Berney S., and Ryan D.T.
- Abstract
Rationale: Patients surviving acute respiratory distress syndrome suffer decrements in physical function and health-related quality of life (HR-QoL); however, it is unclear whether HR-QoL is disproportionately affected in those with H1N1 influenza. Objective(s): The objective was to compare the HR-QoL of patients with a diagnosis of H1N1 influenza who were mechanically ventilated, 12 months after intensive care unit (ICU) discharge with healthy population data and ICU survivor data. Method(s): A prospective, observational, binational, multicenter cohort study was conducted in 11 ICUs in Australia and New Zealand during June-September 2009. Eligible participants were mechanically ventilated in the ICU with a confirmed diagnosis of H1N1 influenza. People were excluded if they were less than 18 years of age or could not speak English. Two validated HR-QoL questionnaires (Short Form-36 version 2 [SF-36], and Assessment of Quality of Life [AQoL]) were administered 1 year after ICU discharge. Measurements and Main Results: Sixty-two patients (48%male) had a median (interquartile range) age of 42 (29-53) years and an APACHE II score of 18.0 (14-20); ventilation days, 10.0 (4-23); and ICU and hospital lengthof stay, 12.5 (7-27) and 20.0 (15-38) days, respectively. Hospital mortality was 7%, and 31% of the cohort received a tracheostomy. The mean (SD) health utility score at 1 year was 0.68 (0.30) compared with the healthy age-matched population (0.81 [0.23]). Themean (SD) SF-36 physical andmental component summary scores were within population normal ranges at 44.4 (12.3) and 45.5 (12.5), respectively. Conclusion(s):Health-related quality of life of Australasian survivors of severe H1N1 influenza was comparable to the healthy population 1 year after ICU discharge. Consensus should be sought on standardization of follow-up time points and outcome measurement. Clinical trial registered with the Australian and New Zealand Clinical Trials Registry (ACTRN12609001037291).Copyrigh
- Published
- 2015
42. Ultrasonography in the intensive care setting can be used to detect changes in the quality and quantity of muscle and is related to muscle strength and function
- Author
-
Parry, SM, El-Ansary, D, Cartwright, MS, Sarwal, A, Berney, S, Koopman, R, Annoni, R, Puthucheary, Z, Gordon, IR, Morris, PE, Denehy, L, Parry, SM, El-Ansary, D, Cartwright, MS, Sarwal, A, Berney, S, Koopman, R, Annoni, R, Puthucheary, Z, Gordon, IR, Morris, PE, and Denehy, L
- Abstract
PURPOSE: This study aimed to (1) document patterns of quadriceps muscle wasting in the first 10 days of admission and (2) determine the relationship between muscle ultrasonography and volitional measures. MATERIALS AND METHODS: Twenty-two adults ventilated for more than 48 hours were included. Sequential quadriceps ultrasound images were obtained over the first 10 days and at awakening and intensive care unit (ICU) discharge. Muscle strength and function were assessed at awakening and ICU discharge. RESULTS: A total of 416 images were analyzed. There was a 30% reduction in vastus intermedius (VI) thickness, rectus femoris (RF) thickness, and cross-sectional area within 10 days of admission. Muscle echogenicity scores increased for both RF and VI muscles by +12.7% and +25.5%, respectively (suggesting deterioration in muscle quality). There was a strong association between function and VI thickness (r = 0.82) and echogenicity (r = -0.77). There was a moderate association between function and RF cross-sectional area (r = 0.71). CONCLUSIONS: Muscle wasting occurs rapidly in the ICU setting. Ultrasonography is a useful surrogate measure for identifying future impairment. Vastus intermedius may be an important muscle to monitor in the future because it demonstrated the greatest change in muscle quality and had the strongest relationship to volitional measures.
- Published
- 2015
43. How Can Clinicians Use Outcome Measures in Routine Care? Knowledge Translation Strategies
- Author
-
Haines, KJ, Skinner, EH, Pastva, A, Berney, S, Denehy, L, Haines, KJ, Skinner, EH, Pastva, A, Berney, S, and Denehy, L
- Published
- 2015
44. Functional outcomes in ICU - what should we be using? - an observational study
- Author
-
Parry, SM, Denehy, L, Beach, LJ, Berney, S, Williamson, HC, Granger, CL, Parry, SM, Denehy, L, Beach, LJ, Berney, S, Williamson, HC, and Granger, CL
- Abstract
INTRODUCTION: With growing awareness of the importance of rehabilitation, new measures are being developed specifically for use in the intensive care unit (ICU). There are currently 26 measures reported to assess function in ICU survivors. The Physical Function in Intensive care Test scored (PFIT-s) has established clinimetric properties. It is unknown how other functional measures perform in comparison to the PFIT-s or which functional measure may be the most clinically applicable for use within the ICU. The aims of this study were to determine (1) the criterion validity of the Functional Status Score for the ICU (FSS-ICU), ICU Mobility Scale (IMS) and Short Physical Performance Battery (SPPB) against the PFIT-s; (2) the construct validity of these tests against muscle strength; (3) predictive utility of these tests to predict discharge to home; and (4) the clinical applicability. This was a nested study within an ongoing controlled study and an observational study. METHODS: Sixty-six individuals were assessed at awakening and ICU discharge. Measures included: PFIT-s, FSS-ICU, IMS and SPPB. Bivariate relationships (Spearman's rank correlation coefficient) and predictive validity (logistic regression) were determined. Responsiveness (effect sizes); floor and ceiling effects; and minimal important differences were calculated. RESULTS: Mean ± SD PFIT-s at awakening was 4.7 ± 2.3 out of 10. On awakening a large positive relationship existed between PFIT-s and the other functional measures: FSS-ICU (rho = 0.87, p < 0.005), IMS (rho = 0.81, p < 0.005) and SPPB (rho = 0.70, p < 0.005). The PFIT-s had excellent construct validity (rho = 0.8, p < 0.005) and FSS-ICU (rho = 0.69, p < 0.005) and IMS (rho = 0.57, p < 0.005) had moderate construct validity with muscle strength. The PFIT-s and FSS-ICU had small floor/ceiling effects <11% at awakening and ICU discharge. The SPPB had a large floor effect at awakening (78%) and ICU discharge (56%). All tests demonstrated responsiven
- Published
- 2015
45. Early mobilization and recovery in mechanically ventilated patients in the ICU: a bi-national, multi-centre, prospective cohort study
- Author
-
TEAM Study Investigators, Hodgson, C, Bellomo, R, Berney, S, Bailey, M, Buhr, H, Denehy, L, Harrold, M, Higgins, A, Presneill, J, Saxena, M, Skinner, E, Young, P, Webb, S, TEAM Study Investigators, Hodgson, C, Bellomo, R, Berney, S, Bailey, M, Buhr, H, Denehy, L, Harrold, M, Higgins, A, Presneill, J, Saxena, M, Skinner, E, Young, P, and Webb, S
- Abstract
INTRODUCTION: The aim of this study was to investigate current mobilization practice, strength at ICU discharge and functional recovery at 6 months among mechanically ventilated ICU patients. METHOD: This was a prospective, multi-centre, cohort study conducted in twelve ICUs in Australia and New Zealand. Patients were previously functionally independent and expected to be ventilated for >48 hours. We measured mobilization during invasive ventilation, sedation depth using the Richmond Agitation and Sedation Scale (RASS), co-interventions, duration of mechanical ventilation, ICU-acquired weakness (ICUAW) at ICU discharge, mortality at day 90, and 6-month functional recovery including return to work. RESULTS: We studied 192 patients (mean age 58.1 ± 15.8 years; mean Acute Physiology and Chronic Health Evaluation (APACHE) (IQR) II score, 18.0 (14 to 24)). Mortality at day 90 was 26.6% (51/192). Over 1,351 study days, we collected information during 1,288 planned early mobilization episodes in patients on mechanical ventilation for the first 14 days or until extubation (whichever occurred first). We recorded the highest level of early mobilization. Despite the presence of dedicated physical therapy staff, no mobilization occurred in 1,079 (84%) of these episodes. Where mobilization occurred, the maximum levels of mobilization were exercises in bed (N = 94, 7%), standing at the bed side (N = 11, 0.9%) or walking (N = 26, 2%). On day three, all patients who were mobilized were mechanically ventilated via an endotracheal tube (N = 10), whereas by day five 50% of the patients mobilized were mechanically ventilated via a tracheostomy tube (N = 18). CONCLUSIONS: Early mobilization of patients receiving mechanical ventilation was uncommon. More than 50% of patients discharged from the ICU had developed ICU-acquired weakness, which was associated with death between ICU discharge and day-90. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT01674608. Registered 14 August 2012.
- Published
- 2015
46. A new two-tier strength assessment approach to the diagnosis of weakness in intensive care: an observational study
- Author
-
Parry, SM, Berney, S, Granger, CL, Dunlop, DL, Murphy, L, El-Ansary, D, Koopman, R, Denehy, L, Parry, SM, Berney, S, Granger, CL, Dunlop, DL, Murphy, L, El-Ansary, D, Koopman, R, and Denehy, L
- Abstract
INTRODUCTION: Intensive care unit-acquired weakness (ICU-AW) is a significant problem. There is currently widespread variability in the methods used for manual muscle testing and handgrip dynamometry (HGD) to diagnose ICU-AW. This study was conducted in two parts. The aims of this study were: to determine the inter-rater reliability and agreement of manual muscle strength testing using both isometric and through-range techniques using the Medical Research Council sum score and a new four-point scale, and to examine the validity of HGD and determine a cutoff score for the diagnosis of ICU-AW for the new four-point scale. METHODS: Part one involved evaluation of muscle strength by two physical therapists in 29 patients ventilated >48 hours. Manual strength testing was performed by both physical therapists using two techniques: isometric and through range; and two scoring systems: traditional six-point Medical Research Council scale and a new collapsed four-point scale. Part two involved assessment of handgrip strength conducted on 60 patients. A cutoff score for ICU-AW was identified for the new four-point scoring system. RESULTS: The incidence of ICU-AW was 42% (n = 25/60) in this study (based on HGD). In part one the highest reliability and agreement was observed for the isometric technique using the four-point scale (intraclass correlation coefficient = 0.90: kappa = 0.72 respectively). Differences existed between isometric and through-range scores (mean difference = 1.76 points, P = 0.005). In part two, HGD had a sensitivity of 0.88 and specificity of 0.80 for diagnosing ICU-AW. A cutoff score of 24 out of 36 points was identified for the four-point scale. CONCLUSIONS: The isometric technique is recommended with reporting on a collapsed four-point scale. Because HGD is easy to perform and sensitive, we recommend a new two-tier approach to diagnosing ICU-AW that first tests handgrip strength with follow-up strength assessment using the isometric technique for muscl
- Published
- 2015
47. Key Measurement and Feasibility Characteristics When Selecting Outcome Measures
- Author
-
Harrold, Megan, Elliott, D., Berney, S., Skinner, E., Harrold, Megan, Elliott, D., Berney, S., and Skinner, E.
- Abstract
Selection of appropriate outcome measures to assess progress in physical rehabilitation across the complete recovery continuum is essential but may pose challenges in clinical practice. This paper examines key measurement and feasibility characteristics for outcome measures, using critical care survivors as an exemplar. With increased survivorship following a critical illness, initiatives to improve the recovery trajectory for patients have become a focus for clinicians and researchers. For this patient cohort, we present a 3-tier framework and use of standing and non-standing patient phenotypes to guide instrument selection. Key measurement issues for clinicians to consider include the responsiveness, criterion validity, and reliability of functional assessment instruments. Patient-centered factors that may influence performance and the effectiveness of assessments include frailty, fatigue, and other varied symptoms of patient discomfort. Suggestions to address these challenges are discussed, specifically prioritizing outcome measurement according to tier, consideration of patient and ICU-related factors, and recommendations to standardize outcome measurement to a core set.
- Published
- 2015
48. Early mobilization and recovery in mechanically ventilated patients in the ICU: a bi-national, multi-centre, prospective cohort study
- Author
-
Harrold, Megan, Hodgson, C., Bellomo, R., Berney, S., Bailey, M., Buhr, H., Denehy, L., Higgins, A., Presneill, J., Saxena, M., Skinner, E., Young, P., Webb, S., Harrold, Megan, Hodgson, C., Bellomo, R., Berney, S., Bailey, M., Buhr, H., Denehy, L., Higgins, A., Presneill, J., Saxena, M., Skinner, E., Young, P., and Webb, S.
- Abstract
Introduction: The aim of this study was to investigate current mobilization practice, strength at ICU discharge and functional recovery at 6 months among mechanically ventilated ICU patients. Method: This was a prospective, multi-centre, cohort study conducted in twelve ICUs in Australia and New Zealand. Patients were previously functionally independent and expected to be ventilated for >48 hours. We measured mobilization during invasive ventilation, sedation depth using the Richmond Agitation and Sedation Scale (RASS), co-interventions, duration of mechanical ventilation, ICU-acquired weakness (ICUAW) at ICU discharge, mortality at day 90, and 6-month functional recovery including return to work. Results: We studied 192 patients (mean age 58.1 ± 15.8 years; mean Acute Physiology and Chronic Health Evaluation (APACHE) (IQR) II score, 18.0 (14 to 24)). Mortality at day 90 was 26.6% (51/192). Over 1,351 study days, we collected information during 1,288 planned early mobilization episodes in patients on mechanical ventilation for the first 14 days or until extubation (whichever occurred first). We recorded the highest level of early mobilization. Despite the presence of dedicated physical therapy staff, no mobilization occurred in 1,079 (84%) of these episodes. Where mobilization occurred, the maximum levels of mobilization were exercises in bed (N = 94, 7%), standing at the bed side (N = 11, 0.9%) or walking (N = 26, 2%). On day three, all patients who were mobilized were mechanically ventilated via an endotracheal tube (N = 10), whereas by day five 50% of the patients mobilized were mechanically ventilated via a tracheostomy tube (N = 18). In 94 of the 156 ICU survivors, strength was assessed at ICU discharge and 48 (52%) had ICU-acquired weakness (Medical Research Council Manual Muscle Test Sum Score (MRC-SS) score <48/60). The MRC-SS score was higher in those patients who mobilized while mechanically ventilated (50.0 ± 11.2 versus 42.0 ± 10.8, P = 0.003). Patients
- Published
- 2015
49. Usual Care Physiotherapy During Acute Hospitalization in Subjects Admitted to the ICU: An Observational Cohort Study
- Author
-
Skinner, E., Haines, K., Berney, S., Warrillow, S., Harrold, Megan, Denehy, L., Skinner, E., Haines, K., Berney, S., Warrillow, S., Harrold, Megan, and Denehy, L.
- Abstract
Background: Physiotherapists play an important role in the provision of multidisciplinary team-based care in the ICU. No studies have reported usual care respiratory management or usual care on the wards following ICU discharge by these providers. This study aimed to investigate usual care physiotherapy for ICU subjects during acute hospitalization. Methods: One hundred subjects were recruited for an observational study from a tertiary Australian ICU. The frequency and type of documented physiotherapist assessment and treatment were extracted retrospectively from medical records. Results: The sample had median (interquartile range) APACHE II score of 17 (13–21) and was mostly male with a median (interquartile range) age of 61 (49–73) y. Physiotherapists reviewed 94% of subjects in the ICU (median of 5 [3–9] occasions, median stay of 4.3 [3–7] d) and 89% of subjects in acute wards (median of 6 [2–12] occasions, median stay of 13.3 [6–28] d). Positioning, ventilator lung hyperinflation, and suctioning were the most frequently performed respiratory care activities in the ICU. The time from ICU admission until ambulation from the bed with a physiotherapist had a median of 5 (3–8) d. The average ambulation distance per treatment had a median of 0 (0–60) m in the ICU and 44 (8–78) m in the acute wards. Adverse event rates were 3.5% in the ICU and 1.8% on the wards. Conclusions: Subjects received a higher frequency of physiotherapy in the ICU than on acute wards. Consensus is required to ensure consistency in data collection internationally to facilitate comparison of outcomes.
- Published
- 2015
50. [O iii]λ5007 AND X-RAY PROPERTIES OF A COMPLETE SAMPLE OF HARD X-RAY SELECTED AGNs IN THE LOCAL UNIVERSE
- Author
-
Ueda, Y., primary, Hashimoto, Y., additional, Ichikawa, K., additional, Ishino, Y., additional, Kniazev, A. Y., additional, Väisänen, P., additional, Ricci, C., additional, Berney, S., additional, Gandhi, P., additional, Koss, M., additional, Mushotzky, R., additional, Terashima, Y., additional, Trakhtenbrot, B., additional, and Crenshaw, M., additional
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.